Is there a scenario to use a CDK4/6 inhibitor apart from abemaciclib for high-risk early breast cancer?
Excluding abemaciclib for early breast cancer treatment, is there a rationale for use of other CDK4/6 inhibitors in this setting? Dr Vidal responds to this question in the Q&A and panel session.